Belite Bio (BLTE)
(Delayed Data from NSDQ)
$48.35 USD
+0.23 (0.48%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $48.10 -0.25 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Belite Bio, Inc. Sponsored ADR [BLTE]
Reports for Purchase
Showing records 1 - 20 ( 24 total )
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Pioneer Drug Designation Granted in Japan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Application For Stargardt Disease Trial in Japan Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 Geographic Atrophy Trial Approved to Start in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive Two-Year Data in Stargardt Disease Presented; Reiterate Buy; Raising PT to $59
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 3 Geographic Atrophy Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 Trial in Stargardt Disease Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Financing Completed; Reiterate Buy; Adjusting PT to $55
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Market Opportunity Intact Despite First FDA-Approved GA Treatment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 Dry AMD Trial Design Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Competitor?s Post Hoc Analysis Validates the Target Patient Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Belite Bio, Inc. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive 12-Month Stargardt Disease Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y